FDA Telehealth Warning Letters In early March 2026, the FDA reportedly issued warning letters to multiple telehealth companies regarding compounded GLP-1 marketing practices, with concerns including misleading marketing claims, implications of equivalence with FDA-approved drugs, and obscuring product sourcing
On the other hand, those with insomnia are said to have poor sleep architecture, or poor sleep patterns that make it difficult to fall and stay asleep
We discuss key translational challenges, including scalable manufacturing processes, quality control of particle size, ligand density, and release kinetics, and long-term biosafety concerns associated with inorganic materials and immune activation
Visit our weight management hub or read our guide on getting started with weight loss to help you on your fat loss journey
Authors acknowledge funding for the study by Dept
It revealed that prescriptions for young people went up by over 600%, and young women were 200% more likely to be taking GLP-1 agonists than young men
Socket sets" loading="lazy"/>